American Journal of Clinical Dermatology,
Journal Year:
2022,
Volume and Issue:
23(5), P. 595 - 603
Published: Sept. 1, 2022
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
skin
condition
that
can
have
tremendous
impact
on
quality
of
life
for
affected
children
and
adults.
First-line
therapy
acute
management
AD
includes
topical
therapies
such
as
corticosteroids,
calcineurin
inhibitors,
and,
more
recently,
the
phosphodiesterase
inhibitor
crisaborole.
Topical
agents
remained
mainstay
decades;
however,
there
has
been
longstanding
need
with
high
efficacy
low
risk
adverse
effects
long-term
use.
Given
ongoing
advances
in
understanding
pathogenesis
AD,
are
novel
targets
pharmacological
intervention.
We
now
an
unprecedented
time
than
40
treatments
pipeline
addition
to
many
developments
horizon.
This
review
summarizes
selected
therapeutic
later
phases
development
target
various
aspects
Janus
kinase
inhibition
(ruxolitinib
delgocitinib),
phosphodiesterase-4
(roflumilast
difamilast),
aryl
hydrocarbon
modulation
(tapinarof),
microbiome.
also
targeted
early
phase
clinical
trials,
including
AMTX-100,
BEN-2293,
PRN473.
Preliminary
findings
tolerability
most
these
promising,
but
further
studies
warranted
evaluate
safety
against
current
standard
care.
Science,
Journal Year:
2022,
Volume and Issue:
376(6596), P. 940 - 945
Published: May 26, 2022
Human
skin
forms
a
protective
barrier
against
the
external
environment
and
is
our
first
line
of
defense
toxic,
solar,
pathogenic
insults.
Our
also
defines
outward
appearance,
protects
internal
tissues
organs,
acts
as
sensory
interface,
prevents
dehydration.
Crucial
to
skin's
function
colonizing
microbiota,
which
provides
protection
pathogens,
tunes
immune
responses,
fortifies
epithelium.
Here
we
highlight
recent
advances
in
understanding
how
microbiota
mediates
multiple
facets
function.
We
discuss
insights
into
pathological
host-microbiota
interactions
implications
for
disorders
distant
organs.
Finally,
examine
microbiota-based
mechanisms
can
be
targeted
prevent
or
manage
impaired
wound
healing.
Allergology International,
Journal Year:
2021,
Volume and Issue:
71(1), P. 31 - 39
Published: Nov. 24, 2021
The
skin
microbiome
is
a
key
component
of
pathogenesis
in
atopic
dermatitis
(AD).
AD
patients
characterized
by
microbial
dysbiosis,
with
reduction
diversity
and
overrepresentation
pathogenic
Staphylococcus
aureus
(S.
aureus).
Recent
exciting
studies
have
elucidated
an
importance
establishing
appropriate
immune
response
to
microbes
early
life
uncovered
the
new
mechanisms
community
dynamics
modulating
our
microbiome.
Several
are
associated
pathogenesis,
proposed
effects
from
S.
Malassezia.
complex
relationships
between
within
consortia
includes
various
species,
such
as
Staphylococcal,
Roseomonas
Cutibacterium
strains,
that
can
inhibit
potential
probiotics
for
skin.
Numerous
now
also
reported
modulate
host
via
communication
keratinocytes,
specialized
cells
adipocytes
improve
health
barrier
function.
This
increased
understanding
microbiota
bioactives
has
led
biotherapeutic
approaches
target
surface
microenvironment
treatment.
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2022,
Volume and Issue:
12
Published: March 7, 2022
The
human
skin
harbors
a
wide
variety
of
microbes
that,
together
with
their
genetic
information
and
host
interactions,
form
the
microbiome.
role
microbiome
in
development
various
diseases
has
lately
gained
interest.
According
to
several
studies,
changes
cutaneous
microbiota
are
involved
pathophysiology
dermatoses.
A
better
delineation
its
interactions
innate
adaptive
immune
systems
could
lead
understanding
these
diseases,
as
well
opportunity
achieve
new
therapeutic
modalities.
present
review
centers
on
most
recent
knowledge
participation
pathogenesis
disorders:
atopic
seborrheic
dermatitis,
alopecia
areata,
psoriasis
acne.
Cell,
Journal Year:
2024,
Volume and Issue:
187(14), P. 3761 - 3778.e16
Published: June 5, 2024
Novel
antibiotics
are
urgently
needed
to
combat
the
antibiotic-resistance
crisis.
We
present
a
machine-learning-based
approach
predict
antimicrobial
peptides
(AMPs)
within
global
microbiome
and
leverage
vast
dataset
of
63,410
metagenomes
87,920
prokaryotic
genomes
from
environmental
host-associated
habitats
create
AMPSphere,
comprehensive
catalog
comprising
863,498
non-redundant
peptides,
few
which
match
existing
databases.
AMPSphere
provides
insights
into
evolutionary
origins
including
by
duplication
or
gene
truncation
longer
sequences,
we
observed
that
AMP
production
varies
habitat.
To
validate
our
predictions,
synthesized
tested
100
AMPs
against
clinically
relevant
drug-resistant
pathogens
human
gut
commensals
both
in
vitro
vivo.
A
total
79
were
active,
with
63
targeting
pathogens.
These
active
exhibited
antibacterial
activity
disrupting
bacterial
membranes.
In
conclusion,
identified
nearly
one
million
an
open-access
resource
for
antibiotic
discovery.
